Amphiphilic ascorbic acid derivatives for anti-microbial surfactants

Overview

This research proposes a novel class of anti-microbial surfactants based on ascorbic acid (vitamin C) derivatized with polyethylene glycol (PEG) or PEG-co-propylene glycol (Pluronic) polymers. The resulting amphiphilic compounds combine ascorbic acid's well-documented antimicrobial activity against bacteria, viruses, and fungi with the surfactant properties of biocompatible block copolymers. By varying polymer molecular weight and composition, key physicochemical properties—including viscosity, solubility, and partition coefficient—can be precisely tuned for specific applications. Both ascorbic acid and Pluronics are bioacceptable for consumer use, making these derivatives promising candidates for safe, effective cleaning and antimicrobial formulations across healthcare, consumer products, and industrial applications.

Technical specifications

Core technology:

• Ascorbic acid (vitamin C) modified via esterification at the 5,6 hydroxyl positions with PEG or Pluronic block copolymers
• Six planned derivatives: three with varying PEG molecular weights and three with varying Pluronic block copolymer molecular weights
• Amphiphilic molecular architecture combining hydrophilic ascorbic acid head with polymer-based hydrophobic/lipophilic character

Key features:

• Tunable properties: Viscosity, solubility, and partition coefficient adjustable through polymer selection
• Biocompatible components: Both ascorbic acid and Pluronics are recognized as safe for consumer and biomedical use
• Synergistic antimicrobial activity: Combines ascorbic acid's antimicrobial properties with surfactant functionality for enhanced cleaning and pathogen reduction
• Facile synthesis pathway: Direct esterification approach leverages established synthetic methods
• Biobased potential: Compatible with biobased ethylene oxide processes for sustainable production

Characterization planned:

• Solution viscosity measurements
• Antimicrobial efficacy testing against common pathogens
• Biocompatibility assessment
• Partition coefficient determination

Technology readiness level

This technology is at an early-to-mid stage of development. The research team has established expertise in ascorbic acid derivative synthesis and biomaterial development for dental applications, with prior intellectual property documented in patent application W02020168201A1. The synthesis methodology is established, and the team plans to produce six initial derivatives for characterization. Future validation will require systematic antimicrobial testing against common pathogens, biocompatibility studies, and partition coefficient measurements. The approach builds on well-characterized starting materials (ascorbic acid and Pluronics) with known biocompatibility profiles, reducing development risk. Commercial deployment will require further optimization, formulation development, and scaled synthesis validation.